Loss of exclusivityMay 2038latest FDA-listed patent expiry
CompanyEpizyme →See this company's full patent-cliff portfolio
Drug detail
Brand name
TAZVERIK
Active ingredient
TAZEMETOSTAT HYDROBROMIDE
Strength
EQ 200MG BASE
Dosage form
TABLET
Route
ORAL
Modality
Small molecule
FDA approval
January 2020
Marketing status
DISCN
Listed patents
Patent
Expires
Type
12168014
May 2038
use U-2852
10786511
December 2035
product
9889138
October 2035
use U-2853
10369155
October 2035
use U-2852
9688665
August 2034
use U-2736
12162865
June 2034
use U-2736
8410088
January 2034
substance, product
10821113
April 2033
substance, product
10245269
April 2033
use U-2854
9394283
April 2033
substance, product
11491163
April 2033
use U-2736
9333217
September 2031
use U-2852
8691507
September 2031
use U-2852
9549931
September 2031
use U-2852
9175331
September 2031
use U-2852
8895245
September 2031
use U-2852
9949999
September 2031
use U-2851
12161645
September 2031
use U-2853
11052093
September 2031
substance, product
12168016
September 2031
use U-2853
10420775
September 2031
use U-2853
10155002
September 2031
use U-2736
9855275
September 2031
use U-2736
9090562
September 2031
substance, product
12168015
September 2031
substance, product
8765732
September 2031
use U-2853
9334527
September 2031
use U-2852
Regulatory exclusivity
Code
Expires
ODE-314
June 2027
ODE-299
January 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
TAZVERIK patent cliff — loss of exclusivity May 2038 | CliffBio